v3.26.1
Condensed Interim Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Apr. 30, 2026 |
Apr. 30, 2025 |
Apr. 30, 2026 |
Apr. 30, 2025 |
|
| OPERATING EXPENSES | ||||
| Advertising and promotion | $ 9,256 | $ 19,323 | $ 20,710 | $ 27,215 |
| Depreciation and amortization | 11,422 | 3,401 | 17,860 | 3,964 |
| Bank charges | 3,644 | 926 | 5,676 | 1,658 |
| Business development | 85,712 | 56,337 | 182,757 | 94,220 |
| Consulting | 1,228,909 | 149,586 | 1,759,107 | 196,596 |
| Filing fees | 17,618 | 150 | 25,258 | 150 |
| Insurance | 4,148 | 0 | 8,400 | 0 |
| Investor relations | 1,085 | 0 | 2,125 | 0 |
| Management and directors' salaries and fees - related parties | 609,613 | 83,116 | 1,335,705 | 292,802 |
| Office and general administrative | 16,867 | 5,720 | 23,843 | 6,349 |
| Professional fees | 325,489 | 95,957 | 592,719 | 101,347 |
| Research and development | 66,605 | 42,465 | 129,167 | 66,133 |
| Total operating expenses | 2,380,368 | 456,981 | 4,103,327 | 790,434 |
| LOSS FROM OPERATIONS | (2,380,368) | (456,981) | (4,103,327) | (790,434) |
| OTHER INCOME (EXPENSES) | ||||
| Gain on conversion of payables | 0 | 0 | 0 | 43,176 |
| Interest income | 84,295 | 0 | 95,586 | 0 |
| Interest expense | 0 | (1,383) | 0 | (4,993) |
| Foreign exchange gain (loss) | (8,210) | 314 | (15,365) | 4,137 |
| Total other income (expenses) | 76,085 | (1,069) | 80,221 | 42,320 |
| LOSS BEFORE TAXES | (2,304,283) | (458,050) | (4,023,106) | (748,114) |
| Income tax benefit (expense) | 0 | 0 | 0 | 0 |
| NET LOSS | $ (2,304,283) | $ (458,050) | $ (4,023,106) | $ (748,114) |
| Net loss per common share | ||||
| Net loss per common share, basic | $ (0.11) | $ (0.05) | $ (0.2) | $ (0.08) |
| Net loss per common share, diluted | $ (0.11) | $ (0.05) | $ (0.2) | $ (0.08) |
| Weighted average of common shares outstanding | ||||
| Weighted average of common shares outstanding, basic | 20,569,664 | 9,505,618 | 20,567,442 | 9,184,944 |
| Weighted average of common shares outstanding, diluted | 20,569,664 | 9,505,618 | 20,567,442 | 9,184,944 |
| X | ||||||||||
- Definition Represents bank charges. No definition available.
|
| X | ||||||||||
- Definition Represents consulting fee expense. No definition available.
|
| X | ||||||||||
- Definition Represents filing fee expense. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of gain on conversion of payables. No definition available.
|
| X | ||||||||||
- Definition Represent the amount of investor relations expenses. No definition available.
|
| X | ||||||||||
- Definition Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for management and incentive fees for performance under arrangement to manage operation, including, but not limited to, managing investment. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|